Clinical Trial Update: Dose Escalation Study of SQ109 in Healthy Adult Volunteers [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of SQ109 in healthy adults has completed, assessing safety and tolerability for potential tuberculosis treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multidrug-resistant Tuberculosis
• Tuberculosis

Drugs mentioned

• SQ109 (SQ109)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: TB Multi-drug Resistant | Phase 1 | Status: COMPLETED